Skip to content
15% off your first order15% off your first order

Ipamorelin 10 mg vial

Growth hormone release

Investigated for selective growth hormone release.

$79.00CAD· $7.90/mg
1
  • Ships from Canada in 1–2 business days
  • Free shipping over $120
  • Place your order, then send the e-Transfer. We pack it as soon as it arrives.

For research use only. Not for human consumption.

Complete your setup

Needles and wipes are free. Water is $19.

Compare. Side by side, from the research.

About Ipamorelin

Ipamorelin is a selective growth-hormone secretagogue. Research examines it specifically for its selectivity, releasing growth hormone with minimal effect on cortisol or prolactin.

How it works

Receptor Selectivity
Studied for acting at the ghrelin receptor with minimal associated cortisol or prolactin response.
Pulsatile Release
Explored for producing a release pattern that resembles the body's own rhythm.
Read the full research

What you need

  • Bacteriostatic Water
  • Needles
  • Alcohol Wipes
  • A protocol guide comes with every order

Shipping & payment

  • Packed and dispatched within 1–2 business days
  • Delivered across Canada in 2–5 business days, tracked
  • Temperature-controlled packaging where the product needs it
  • Free shipping on orders over $120
  • Prices in CAD · pay by Interac e-Transfer
Format
Lyophilised powder in a sealed vial
Strength
10 mg per vial
Storage
Refrigerate, away from light. Once reconstituted, keep refrigerated and use within the window on the insert.
Reconstitution
2 mL bacteriostatic water for this 10 mg vial (5 mg/mL)
Route in research
Subcutaneous
Target
GHS-R1a
SKU
IP10

Handling

  1. 1ReconstituteAdd bacteriostatic water down the side of the vial. Swirl, never shake. Agitation damages the peptide chain.
  2. 2StoreRefrigerate at 2–8°C once mixed. Reconstituted peptide is stable for the window given in your protocol guide.
  3. 3Measure with the calculator Use an insulin syringe at the units your protocol specifies. Rotate sites and log what you take.
Purity
High-performance liquid chromatography (HPLC), by an independent laboratory
Identity
Mass spectrometry, on the same batch
How often
Every batch
COA
The certificate of analysis is matched to the lot code printed on your vial
Evidence
Preclinical

Check your lot

Every vial carries a lot code. Enter it, or scan the QR on the label, to see its expiry and certificate of analysis.

PreclinicalThe primary studies on Ipamorelin are animal studies of growth hormone release and bone growth, while more recent reviews discuss it among unapproved peptides, so controlled human evidence is limited.

What research examines

  • Selective growth hormone release
  • Minimal cortisol and prolactin response
  • Longitudinal bone growth in rats
  • Body composition in reviews of GH secretagogues
  • Musculoskeletal and sports medicine peptide research

Reported in studies

  • Human safety data are limited
  • Early research reported minimal effects on cortisol and prolactin
  • Recent reviews assess it among unapproved peptide therapies
  • Reviews discuss its use in sport and bodybuilding in a doping context
Read the full research page· 5 cited studies

Published research protocols

300 mcg, 5 days on 2 days off, pm fasted

Research protocols have used 200–500 mcg per administration, 5 days per week (evening, fasted), in 8-week blocks with 4 weeks off.

For research use only. These figures summarize published research protocols. They are not instructions or medical advice.

Measure with the calculator

CoreX AI

Ask about Ipamorelin

Plain answers, from the basics to the studies.

Research information, not medical advice.

Often researched with Ipamorelin

FAQ

Questions, answered

  • Ipamorelin is a synthetic growth hormone secretagogue. A 1998 paper described it as the first selective compound of this type. Research has focused on its selectivity. It stimulates growth hormone release with minimal reported effect on cortisol or prolactin, which set it apart from earlier secretagogues with broader hormonal activity. It is sold for laboratory research use only.

  • Research describes Ipamorelin as an agonist at the ghrelin receptor, GHS-R1a. Activating this receptor has been studied as a way to stimulate growth hormone release from the pituitary. Research has also explored whether Ipamorelin produces a pulsatile release pattern that resembles the body's own growth hormone rhythm. Its selectivity for growth hormone over cortisol and prolactin is the feature most often examined.

  • Early studies examined its selective growth hormone releasing activity. A 1999 study in rats reported that it induced longitudinal bone growth. More recent reviews discuss Ipamorelin alongside other growth hormone secretagogues in body composition research, orthopaedic and sports medicine, and healthy aging. These reviews generally frame it as an investigational compound, and controlled human outcome data remain limited.

  • Human safety data for Ipamorelin are limited. Early research emphasized its minimal effect on cortisol and prolactin compared with earlier secretagogues. Recent reviews assess the safety and efficacy of unapproved peptide therapies, including compounds of this class. Other reviews examine its use in recreational and professional sport and bodybuilding in a doping context. Adverse events are not comprehensively summarized in the cited studies.

  • Research protocols have used 200–500 mcg per administration, 5 days per week, in the evening in a fasted state. These protocols ran in 8-week blocks followed by 4 weeks off, and the route described is subcutaneous. These figures describe research protocols only. Each CoreX order ships with a protocol guide for laboratory reference.

Vial · Pen

Dual-agonist weight research

Tirzepatide · 2 sizes

$139/ 30 mg vial

Vial · Pen

Triple-agonist weight research

GLP-3R · 4 sizes

$119/ 10 mg vial